{"Symbol": "CPHR", "AssetType": "Common Stock", "Name": "Cipher Pharmaceuticals Inc", "Description": "Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical dermatology company in the United States. The company offers CIP-ISOTRETINOIN, a formulation for the treatment of acne; CIP-FENOFIBRATE, a patented formulation of the active ingredient fenofibrate to treat hyperlipidemia; and CIP-TRAMADOL ER, a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain. It also provides Beteflam Patch, a self-adhesive medicated plaster for the treatment of inflammatory skin conditions, such as plaque psoriasis; Dermadexin, a topical barrier-repair cream for the treatment of seborrheic dermatitis; and Pruridexin, a topical cream for the treatment of chronic pruritis. In addition, the company is developing Ozenoxacin, which completed Phase III clinical trials to treat adult and paediatric patients with impetigo; ASF-1096, a product candidate in Phase II that is being investigated as a treatment for discoid lupus erythematosus; and CF101, which completed Phase II/III double-blind, placebo-controlled study to treat patients with moderate to severe plaque psoriasis. It has collaborative partnership with Galephar Pharmaceutical Research, Inc. Cipher Pharmaceuticals Inc. was founded in 2004 and is headquartered in Mississauga, Canada.", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "Other", "Industry": "Other", "Address": "None", "FullTimeEmployees": "0", "FiscalYearEnd": "None", "LatestQuarter": "None", "MarketCapitalization": "0", "EBITDA": "0", "PERatio": "None", "PEGRatio": "0", "BookValue": "0", "DividendPerShare": "None", "DividendYield": "None", "EPS": "-0.99", "RevenuePerShareTTM": "0", "ProfitMargin": "0", "OperatingMarginTTM": "0", "ReturnOnAssetsTTM": "0", "ReturnOnEquityTTM": "0", "RevenueTTM": "0", "GrossProfitTTM": "0", "DilutedEPSTTM": "0", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "0", "AnalystTargetPrice": "7.15", "TrailingPE": "0", "ForwardPE": "0", "PriceToSalesRatioTTM": "0", "PriceToBookRatio": "0", "EVToRevenue": "0", "EVToEBITDA": "0", "Beta": "None", "52WeekHigh": "None", "52WeekLow": "None", "50DayMovingAverage": "0", "200DayMovingAverage": "0", "SharesOutstanding": "0", "SharesFloat": "0", "SharesShort": "0", "SharesShortPriorMonth": "0", "ShortRatio": "0", "ShortPercentOutstanding": "0", "ShortPercentFloat": "0", "PercentInsiders": "0", "PercentInstitutions": "0", "ForwardAnnualDividendRate": "0", "ForwardAnnualDividendYield": "0", "PayoutRatio": "0", "DividendDate": "None", "ExDividendDate": "None", "LastSplitFactor": "None", "LastSplitDate": "None"}